培哚普利对无症状充血性心力衰竭的早期干预  

Primary intervention with Acertil on asymptomatic congestive heart failure

作　　者：刘纪改[1] 袁春媛[1] 

机构地区：[1]山东省千佛山医院,山东济南250014

出　　处：《实用医药杂志》2003年第6期405-406,共2页Practical Journal of Medicine & Pharmacy

摘　　要：目的为延缓和逆转慢性充血性心力衰竭(心衰)的发生,探讨培哚普利对无症状心衰的预防作用。方法对36例无症状心衰患者在对因治疗基础上给以培哚普利2～4mg/d口服,观察治疗前后的血压、心率及心功能变化,疗程24个月。结果治疗前后平均血压分别为105.7±13.5和99.0±11.3mmHg(P<0.05);心率分别为82.1±15.5次/min和81.1±11.61次/min(P>0.05);PCWP分别为13.5±4.9mmHg和11.3±4.1mmHg(P<0.05);EF分别为43.6%±7.0%和58.1%±7.5%(P<0.05);临床心衰发生率及再住院率均为3%;无1例病死。结论培哚普利早期干预治疗无症状心衰可显著改善心功能,延缓临床心衰的发生,降低再住院率和病死率。Objective To explore the reversible and delayed effect of Acertil o n the patients with asymptomatic congestive heart failure (CHF). Methods Thirty-six patients with asymptomatic CHF accepted Acertil 2-4mg, p.o.daily. The blood pressure, heart rate, heart function were measured by echocardiography and foll owed up for at least 24 months. Results The mean blood pressure were 105.7±13. 5,99.0±11.3mmHg(P<0.05); the heart rate were 82.1±15.5,81.1±11.6bpm (P>0.05); the pulmonary wedge pressure (PCWP) were 13.5±4.9,11.3±4.1 mmHg(P<0.05); the ejection fraction (EF) were 43.6%±7.0%,58.1%±7.5%(P<0.05). During the follow u p, the incidence and readmission rate were 3%; nobody wasdead. Conclusion Prima ry intervention of Acertil can obviously improve cardiac function, delay or reve rse the onset of clinical CHF, and lower the mortality and readmission rate.

关 键 词：心力衰竭 早期干预 心功能 培哚普利 预防作用 无症状心衰 

分 类 号：R541.61[医药卫生—心血管疾病]